ZURA Stock Summary and Trading Ideas (Zura Bio Limited - Class A | NASDAQ:ZURA)

Zura Bio Ltd is a clinical-stage biotechnology company developing novel medicines for patients with autoimmune and inflammatory diseases, including serious and debilitating conditions with unmet medical need. These diseases are often chronic, biologically complex, and difficult to treat, and many patients do not achieve durable disease control with existing therapies. The company has in-licensed three clinical-stage product candidates: Tibulizumab (ZB-106), a bispecific antibody targeting IL-17A and BAFF; Crebankitug (ZB-168), an IgG1 monoclonal antibody targeting IL-7R; and Torudokimab (ZB-880), an IgG4 monoclonal antibody targeting IL-33.

Zura Bio Limited - Class A trades on the NASDAQ stock market under the symbol ZURA.

As of July 2, 2026, ZURA stock price climbed to $5.17 with 888,162 million shares trading.

ZURA has a beta of -0.52, meaning it tends to be less sensitive to market movements. ZURA has a correlation of 0.00 to the broad based SPY ETF.

ZURA has a market cap of $490.53 million. This is considered a Small Cap stock.

In the last 3 years, ZURA traded as high as $8.31 and as low as $.97.

The top ETF exchange traded funds that ZURA belongs to (by Net Assets): IWM, IWO, VXF, IWC, SBIO.

ZURA has outperformed the market in the last year with a price return of +392.4% while the SPY ETF gained +21.8%. However, in the short term, ZURA had mixed performance relative to the market. It has underperformed in the last 3 months, returning -14.3% vs +14.0% return in SPY. But in the last 2 weeks, ZURA shares have fared better than the market returning +42.8% compared to SPY +1.0%.

ZURA support price is $4.69 and resistance is $5.32 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that ZURA shares will trade within this expected range on the day.